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Highlights 
 More people with constipation use probiotics compared to those without constipation  
 A strong predictor for probiotic use in the general population is having constipation 
 The most common sources of information regarding probiotics are TV adverts 
 Most GPs and gastroenterology specialists however do not recommend them for 
constipation. 
 Most GPs and gastroenterology do not believe probiotics have been tested for 
constipation. 
 
ABSTRACT 
Objective: To assess the use and perceived effectiveness of probiotics by the general 
population (with or without self-reported constipation), and their recommendation and 
perceived effectiveness by general practitioners (GPs) and gastroenterology specialists.  
Research Methods & Procedures: A cross-sectional, primarily online, survey was undertaken. 
Responses were compared between groups using chi squared tests, and logistic regression was 
employed to identify predictors of probiotic use.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
3 
 
Results: 2,557 members of the general population (1,623 self-reported constipation, 934 
without), 411 GPs and 365 GI specialists completed the survey. 37% of the general population 
with self-reported constipation had tried probiotics, compared to 11% of those without 
(p<0.001), with the strongest predictors of use being the belief that probiotics have been tested 
in appropriate studies (OR 1.9; p<0.001), receiving a formal constipation diagnosis by a doctor 
(OR 1.6, p<0.001) and a self-diagnosis of constipation (OR 1.6; p<0.001). Only 26% of GPs and 
34% of gastroenterology specialists recommended probiotics for constipation (p=0.012). Almost 
two thirds of the general population (65%) believed that probiotics had been tested in studies 
for constipation, whereas only 35% GPs and 43% gastroenterology specialists believed this 
(p<0.001).  
Conclusion: There is high usage and perceived evidence for probiotics among people with 
constipation. However, most GPs and gastroenterology specialists do not recommend them for 
constipation suggesting a need for further research, and education of health care professionals 
on existing evidence. 
INTRODUCTION 
Chronic constipation is a common bothersome disorder affecting approximately 14% of the 
general population (1). Although there are several management options for constipation, 
typically a range of laxative compounds, approximately half of patient are dissatisfied with 
current treatment strategies (2). Indeed, the vast majority of people with constipation self-
manage using over-the-counter products (3) and constipation has been shown to be the third 
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most cited symptom in patients attending an outpatient GI clinic for which complementary and 
alternative therapies (CAMs) are used (4). 
Over the past decade, there has been an increase in research investigating the effect of 
probiotics in chronic constipation. Probiotics are live micro-organisms that, when administered 
in adequate amounts, confer health benefits to the host (5). Particularly, various probiotic 
strains have been shown to have beneficial effects on several constipation-related symptoms 
(e.g. stool frequency and consistency), such as Bifidobacteria lactis (6; 7; 8). Probiotics may help 
normalise gut motility and improve constipation symptoms via their effect on the gut 
microbiota and their metabolites, the central and enteric nervous system, as well as the 
immune system (9). 
Probiotics are widely available as either probiotic-containing food products (e.g. yoghurts, 
fermented milks) or probiotic supplements (e.g. sachets, capsules) and are can be purchased in 
supermarkets, health shops, pharmacies and online. Overall, 45% of patients with GI conditions 
who use CAMs for their GI symptoms commonly use probiotics, while adults with GI conditions 
are more likely to use probiotic supplements than adults without a GI condition (10). However, 
there is lack of evidence as to whether people with constipation use probiotics specifically to 
manage constipation-related symptoms, and how effective they believe they are. 
Probiotics are commonly recommended by general practitioners for the management of GI 
disorders, such as chronic diarrhoea and IBS (11). For example, a UK survey that included over 
1500 primary care health professionals (e.g. GPs, dietitians, nurses) showed that 78% of GPs 
advise probiotic use for their patients, with constipation being the 5th most common condition 
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for recommendation (12).  Nevertheless, specific use in constipation is little researched. 
Furthermore, there is no evidence as to whether GI specialists recommend probiotics for 
constipation and their perceived effectiveness. 
The aim of this study was to assess the use and perceived effectiveness of probiotics by the 
general population (with or without self-reported constipation), as well as their 
recommendation and perceived effectiveness by general practitioners (GPs) and 
gastroenterology specialists. The hypothesis was that people with self-reported constipation 
more commonly use probiotics than those without self-reported constipation. 
 
MATERIAL AND METHODS 
This was a cross-sectional questionnaire survey using a self-administered questionnaire. Ethical 
approval was granted by the Newcastle and North Tyneside 2 NHS Research Ethics Committee 
(reference ID: 15/NE/0060) on 13 February 2015. 
Participants 
Members of the general population (with and without self-reported constipation), as well as 
GPs and GI specialists were recruited. Inclusion criteria for members of the general population 
were as follows: men and women aged 18 years or above; individuals who lived in the UK; and 
individuals who were able to consent, whereas exclusion criteria were: individuals with severe 
gastrointestinal diseases (e.g. inflammatory bowel disease); pregnancy or lactation; and 
individuals who were health professionals. Inclusion criteria for GPs and GI specialists were the 
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following: being in clinical contact with patients; and living in the UK. Both registrars and 
consultants in gastroenterology or colorectal surgery were eligible for the GI specialists group.  
An opportunistic sampling technique was adopted. The general population were recruited via 
circular emails and advertising in eight UK universities, on advertising websites, in magazines, in 
newspapers and via healthy volunteer databases across the UK. In order to ensure 
representation of self-reported constipated individuals within the sample, circular emails were 
also sent to people with constipation-related symptoms who have participated in previous trials 
run by the study team members. 
GPs were recruited via an advert placed in the monthly newsletter of the Royal College of 
General Practitioners, and individual personalised emails were sent to all members of the 
Primary Care Society for Gastroenterology (n=475). Furthermore, 90 GP practices in South and 
East London were contacted by telephone and/or attended in person and 34 GP meetings in 
Greater London were attended where questionnaires were distributed for completion. 
GI specialists were recruited through personalised emails, sent to all members of the British 
Society of Gastroenterology (n=2,202) and all members of the Association of Coloproctology of 
Great Britain and Ireland (n=668). Two GI conferences were attended in person where 
questionnaires were distributed for completion.  
In order to limit sampling bias, various approaches were adopted to increase response rate, 
including: non-monetary incentive offered to participants (prize draw), personalised emails 
were sent to recruit doctors and the advertisements stated the number of participants 
recruited to date (13). 
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The sample size calculation was based on the margin of random sampling error (14; 15). On the 
basis of generating a margin of error of <5% at a 95% confidence level, it was calculated that a 
sample size of at least 900 members of the general population, 400 GPs and 325 GI specialists 
was needed. 
Questionnaire 
In the absence of a previously validated questionnaire, a questionnaire was developed to 
investigate perceptions of probiotic use and effectiveness. The self-administered questionnaire 
included closed-ended questions as well as free-text boxes where appropriate. The 
questionnaire included the following sections: (1) bowel habits and constipation status (2) 
probiotic use and effectiveness, and (3) demographics. The questionnaire was piloted in five 
people for the terminology used, the clarity of the questions, the response sets and the length 
of the questionnaire. 
Initially, members of the general population were asked whether they considered themselves 
to have constipation (yes/no), which was used to define participants as having self-reported 
constipation or not. All members of the general population were also asked whether they had 
ever received a formal diagnosis of constipation by a doctor (yes/no). They were then asked 
about their use of probiotics, and their reason for using them (symptoms of constipation, 
digestive comfort, general health, for reasons not related to health). If participants reported 
using probiotics for symptoms of constipation, digestive comfort or general health, they were 
then asked about the products used overall, the source of information that led them to use 
probiotics, their perceived effectiveness (using a 4 point Likert scale from 1 to 4; 1=not effective 
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at all, 2=a little effective, 3=moderately effective, 4=very effective), and their perceptions of the 
scientific evidence for their effectiveness in constipation.  
GPs and GI specialists were asked regarding their recommendations for using probiotics in 
constipation, the products they recommended, their perceived effectiveness, and their 
perceptions of the scientific evidence for their effectiveness in constipation. 
The questionnaire was available online for the general population, whereas online and paper 
copies were available for GPs and GI specialists to facilitate recruitment.  Prior to completing 
the questionnaire, participants were required to read a comprehensive participant information 
sheet; this was provided on the initial page on both the electronic and hard-copy of the 
questionnaire. The participant information sheet clearly stated that participant were providing 
informed consent by completing the questionnaire. 
Statistical analysis 
Descriptive statistics were used to summarise and describe data. For continuous data, mean 
(SD) were reported. Associations between categorical variables and counts (e.g. differences in 
use of probiotics between constipated and non-constipated) were analysed using a Chi-squared 
test. A step-wise logistic regression model was used to determine the effect of factors on the 
use/recommendation of probiotics for the management of constipation. P values of < 0.05 
were considered statistically significant. 
 
RESULTS 
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Participant characteristics 
Overall, 2,557 members of the general population (1,623 without self-reported constipation, 
934 with self-reported constipation), 411 GPs and 365 GI specialists were eligible. The GI 
specialist group comprised 224 (61%) gastroenterologists and 141 (39%) colorectal surgeons; of 
these 269 (74%) were consultants and 96 (26%) were registrars. The participant’s 
characteristics are shown in Table 1. Those with constipation were slightly older, more likely to 
be female and fewer had higher qualifications, compared with those without constipation. The 
ethnic profile of the general population broadly reflected that of the UK general population (16).  
Participants with self-reported constipation had significantly lower stool frequency and harder 
stools compared to those without self-reported constipation (Table 1). Those with constipation 
who were currently using probiotics had a similar stool frequency to those not currently using 
probiotics (3.7 ± 1.0 bowel movements/week vs 3.6 ± 1.0 bowel movements/week, 
respectively; p=0.2), and they also had a similar stool consistency (2.5 ± 1.4 stool type vs 2.6 ± 
1.5 stool type, respectively; p-0.590). 
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†
Independent t-test p value.
 ‡
Chi-squared p value.  
Data within each row that do not share the same subscript letter are significantly different. 
Table 1: Participants characteristics by study group. 
 
Use and recommendation of probiotics 
As shown in Table 2, the majority of the general population with constipation had previously 
used or were currently using probiotics (563/934, 60%), which was significantly greater than the 
proportion of those without constipation (832/1623, 51%) (p<0.001). Of those who previously 
or currently used probiotics, 346 (62%) with constipation had done so for their gut health 
(including constipation symptoms, digestive discomfort), while only 181 (22%) of those without 
self-reported constipation had done so for gut health (e.g. digestive discomfort) (p<0.001). In 
those with constipation, 123/934 (13%) were currently using probiotics for their gut health (e.g. 
 General population    
 
Without 
constipation 
(n=1,623) 
Self-reported 
constipation 
(n=934) 
GPs 
(n=411)  
GI 
specialists 
(n=365) P value 
Age, years, mean (SD) 37.8 (14.5)
 
40.7 (13.5) - - <0.001
†
 
Females, n (%) 1,128 (70)
a 
822 (88)
 b
 211 (51)
 c
 102 (28)
 d
 <0.001
‡
 
Ethnicity, n (%)      
White 1,419 (87)
 a
 814 (87)
 a
 197 (48)
 b
 244 (67)
 c
 
<0.001
‡
 
Asian / Asian British 110 (7)
 a
 54 (6)
 a
 159 (39)
 b
 87 (24)
 c
 
Black/African/Caribbean/British 32 (2)
 a,b
 29 (3)
 b
 31  (8)
 c
 2 (1)
 a
 
Mixed  46 (3)
 a
 28 (3)
 a
 12 (3)
 a
 12 (3)
 a
 
Other 16 (1)
 a
 9 (1)
 a
 12 (3)
 a,b
 20 (6)
 b
 
Education, n (%)      
No formal qualifications 46 (3)
 a 
 37 (4)
 a
 - - 
<0.001
‡
 
Vocational qualifications 120 (7)
 a
 141 (15
 
)
 b
 - - 
School level qualifications 572 (35)
 a
 383 (41)
 b
 - - 
Undergraduate degree 553 (34)
 a
 267 (29)
 b
 - - 
Postgraduate degree 332 (21)
 a
 106 (11)
 b
 - - 
Stool frequency / wk, mean (SD) 8.0 (4.3) 4.5 (4.4) - - <0.001
†
 
Stool consistency, Bristol stool form scale, 
mean (SD) 
3.6 (1.0) 2.8 (1.5) - - <0.001
†
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constipation symptoms, digestive discomfort) compared to only 42/1623 (3%) of those without 
constipation (p<0.001). The odds ratio for previous or current probiotic use for gut health in 
constipation was 4.7 (95% CI 3.8 to 5.7, p<0.001), while the odds ratio for current use only was 
5.7 (95% CI 4.0 to 8.2, p<0.001). 
The probiotic most commonly used for gut health by those without constipation was the 
probiotic-containing food product Actimel (followed by Activia and Yakult) and for those with 
constipation was Activia (followed by Actimel and Yakult) (Table 2). The probiotic most 
commonly recommended for constipation by GPs was the probiotic supplement VSL#3, and by 
GI specialists was Yakult (Table 2). Only 10 (10%) of GPs and 3 (2%) of GI specialists recommend 
probiotics as a first-line treatment. 
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Table 2: The use of probiotic-containing food products and probiotic supplements by the general population (with or without self-
reported constipation), and their recommendation by General Practitioners (GPs) and GI specialists. 
 General population    
 Without self-reported 
constipation 
(n=1,623) 
With self-reported 
constipation 
(n=934) 
GPs 
(n=411)  
GI specialists 
(n=365) 
Chi-
squared 
P value 
Probiotic use (for any reason)      
Never used before 791 (49%)
a 
371 (40%)
 b
 - -  
Previously used 649 (40%)
 a
 404 (43%)
 a
 - - <0.001 
Currently using 183 (11%)
 a
 159 (17%)
 b
 - -  
Probiotic use specifically for gut health      
Previously or currently using 181 (11%),  346 (37%) - - <0.001 
Currently using only 42 (3%),  123 (13%)  - - <0.001 
Recommend probiotics for constipation - - 105 (26%) 124 (34%) 0.012
†
 
Prescribe probiotics for constipation - - 22 (5%) 41 (11%) 0.004
†
 
Using/recommending probiotics for gut health as a:      
First-line treatment - 79/346 (23%)
 a
 10/105 (10%)
 b
 3/124 (2%)
 
 
<0.001 In addition to other treatments - 215/346 (62%)
 a
 77/105 (73%)
 a,b
 107/124 (86%)
 b
 
After other treatments failed - 52/346 (15%)
 a
 18/105 (17%)
 a
 20/124 (16%)
 a
 
Probiotics used/recommended for gut health, n (% of users):      
Probiotic-containing food products      
Actimel 137 (76%)
 a
 260 (75%)
 a
 43 (41%)
 b
 65 (50%)
 b
 <0.001 
Activia 132 (73%)
 a
 276 (80%)
 a
 40 (38%)
 b
 59 (46%)
 b
 <0.001 
Yakult 123 (68%)
 a
 226 (65%)
 a
 41 (39%)
 b
 75 (58%)
 a
 0.001 
Probiotic supplements      
VSL#3 4 (2%)
 a
 5 (1%)
 a
 69 (53%)
 b
 22 (21%)
 c
 <0.001 
Acidophilus 50 (28%
 
)
 a
 97 (28%)
a
 19 (18%)
 a,b
 19 (15%)
 b
 0.006 
Probio 7 14 (8%)
 a
 32 (9%)
 a
 3 (3%)
 a
 15 (12%)
 a
 0.099 
Multibionta 22 (12%)
 a,b
 56 (16%)
 b
 8 (6)
 a
 6 (6%)
 a
 0.003 
Other 20 (11%)
 a
 85 (25%)
 b
 49 (47%)
 c
 30 (23%)
 b
 <0.001 
Values are n (%), unless otherwise stated. 
†
Fisher’s exact test.   
Data within each row that do not share the same subscript letter are significantly different. 
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The sources of information for probiotic use for gut health in the general population are shown 
in Figure 1. The most common sources of information regarding probiotics were TV adverts, 
seeing a product in a shop and family. GPs were a source of information regarding the use of 
probiotics for only 14 (8%) of individuals without constipation and 24 (7%) with constipation. 
Specialist doctors were a source of information regarding probiotics for only 2% of the general 
population, irrespective of constipation status (Figure 1). 
 
Figure 1: Sources of information for probiotic use for gut health in the general population, 
including those with (n=346) and without (n=181) constipation. Comparisons between groups 
are via a Chi-squared test. †Fisher’s Exact Test. 
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Factors associated with probiotic use 
In the general population as a whole, factors associated with previous or current probiotic use 
for health were having received a formal diagnosis of constipation by a medical practitioner (OR 
1.6; 95% CI 1.3-1.9), self-reporting constipation (OR 1.6; 95% CI 1.3-1.9) and believing that 
probiotics have been tested in research studies (OR 1.9; 95% CI 1.6-2.2) (Table 3). Having a 
university degree was also a factor associated with probiotic use for health (OR 0.62; 95% 0.51-
0.75). 
For those with self-reported constipation, factors associated with probiotic use were having 
visited a complementary and alternative therapist for their constipation symptoms (OR 2.5; 
95% CI 1.3-4.9) and believing that probiotics have been tested in research studies (OR 2.1; 95 
%CI 1.6-2.8) (Table 3). 
For people without self-reported constipation, factors associated with probiotic use was 
actually having received a formal diagnosis of constipation by a medical practitioner (OR 1.9; 
95% CI 1.4-2.7), as well as meeting the Rome IV criteria for chronic constipation (even though 
they do not consider themselves to have constipation) (OR 1.3; 95% CI 1.0-1.6) (Table 3). 
For GPs, the factor associated with recommending probiotics for constipation was believing 
that probiotics have been tested in research studies (OR 1.9; 95 %CI 1.2-3.03). No factors were 
associated with recommending probiotics for constipation among GI specialists (Table 3). 
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 General Population     
All 
Without self-reported 
constipation 
With self-reported 
constipation GPs GI specialists 
OR (95% CI) P  OR (95% CI) P  OR (95% CI) P  OR (95% CI) P  OR (95% CI) P  
Age (per year) 1.02 (1.01-1.02) <0.001 1.02 (1.01-1.02) <0.001 1.02 (1.01-1.03) <0.001 - - - - 
Gender (compared to females) 0.62 (0.51-0.75) <0.001 0.65 (0.52-0.82) <0.001 0.54 (0.35-0.81) 0.003 - - - - 
University degree 1.50 (1.27-1.77) <0.001 1.21 (1.09-1.34) <0.001 1.76 (1.32-2.35) <0.001 - - - - 
Diagnosis of constipation via:           
Self-reported constipation 1.55 (1.30-1.86) <0.001 - - - - - - - - 
Rome IV diagnosis  - - 1.28 (1.02-1.60) 0.032 - - - - - - 
Formal diagnosis by a doctor 1.56 (1.25-1.93) <0.001 1.93 (1.37-2.72) <0.001 - - - - - - 
Believe probiotics have been tested 1.85 (1.56-2.19) <0.001 1.70 (1.36-2.12) <0.001 2.06 (1.56-2.72) <0.001 1.91 (1.20-3.03) 0.006   
Professional visited for constipation: - - - - - - - - - - 
Specialist doctor - - - - 1.67 (1.10-2.53) 0.015 - - - - 
Complementary and alternative practitioner - - - - 2.46 (1.25-4.85) 0.010 - - - - 
 
Table 3: Significant predictors of probiotic use for general and gut health by the general population, and significant predictors for 
probiotic recommendation for constipation by doctors. 
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Perceptions of the evidence and effectiveness of probiotics  
The majority of the general population (1,662, 65%) believed that probiotics have been tested 
in research studies for the treatment of constipation, contrary to the perceptions of GPs (144, 
35%) and GI specialists (156, 43%) in whom only a minority believe probiotics had been tested 
in constipation (p<0.001) ( 
Table 2). There was no significant difference among people with constipation (2.1 ± 0.8 using a 
4 point Likert scale), GPs (2.3 ± 0.8) and GI specialists (2.1 ± 0.5) on the perceived degree of 
effectiveness of probiotics for the relief of constipation (p=0.209) 
In order to further investigate the effect of the perceived evidence for probiotics and 
constipation on the perceived effectiveness of probiotics, each group was dichotomised on the 
basis of whether they thought probiotics had been tested for constipation or not. GI specialists 
who thought probiotics have been tested for constipation believed that they were significantly 
more effective for the management of constipation, compared to those who believed 
probiotics have not been tested for constipation (2.5 ± 0.8 vs 2.0 ± 0.6, p=0.001). This difference 
was not demonstrated in GPs (p=0.480). 
People with constipation that were currently using probiotics believed probiotics were 
significantly more effective compared to those that were previously using probiotics (2.4 ± 0.9 
vs 1.9 ± 0.8, p<0.001). Similarly, significantly more people with constipation who were currently 
using probiotics for gut health believed they have been tested in research studies for 
constipation, compared to those that had previously used probiotics (83% vs 45%, p=0.003). 
This effect was not shown by those without self-reported constipation (p=0.842). 
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DISCUSSION 
Significantly more people with self-reported constipation use probiotics for their health, 
compared to those without self-reported constipation. Indeed, four times as many people with 
constipation as those without constipation were currently using probiotics, confirming that 
probiotics are used by people with constipation as a management strategy. Another survey has 
likewise shown that constipation was the third most commonly cited reason for the use of 
complementary and alternative medicines among patients attending a gastroenterology clinic, 
with the most common product used being probiotics (4). Probiotics may be perceived as a 
“natural” alternative to medications and are considered by the public to be safer and pose 
fewer health risks (17).  
Despite the fact that some people with constipation use probiotics for their symptoms, the 
majority of GPs and GI specialists do not recommend probiotics for constipation management. 
Although a US survey of gastroenterologists has shown that over-the-counter products 
dominate primary therapy for constipation, that study did not measure probiotic use (18). 
Specifically, fibre supplements and laxatives were the most commonly recommended 
treatments recommended by gastroenterologists (18). According to the current findings, a 
possible reason for not recommending probiotics for constipation might be the perceived lack 
of research evidence in this area. Indeed, this study showed that believing probiotics have been 
tested for their effectiveness in constipation was a significant predictor of probiotic 
recommendation by GPs, but not for GI specialists. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
18 
 
The majority of the general population believe that probiotics have been tested in research 
studies for the treatment of constipation, whereas the majority of GI specialists and GPs do not 
believe this to be the case. These findings might explain the higher rate of probiotic use in the 
general population, compared with the lower rates of probiotic recommendation by GPs and GI 
specialists. However, although there was a significant difference between the general 
population and medical practitioners in the perceived evidence on probiotics and constipation, 
there was no difference in the perceived effectiveness of probiotics for constipation. As 
expected, it was shown that the GI specialists who believed that probiotics had been tested for 
their treatment of constipation thought that probiotics were significantly more effective for the 
management of constipation, compared to those who believed probiotics have not been 
tested. This highlights the fact that research is crucial for shaping GI specialists’ perceptions 
regarding the effectiveness of probiotics in constipation, and emphasizes the need for 
communicating the findings of relevant research studies to medical professionals. Although 
several RCTs investigating the effect of probiotics in patients with constipation have already 
been published (8), the fact that the vast majority of GPs and GI specialists do not believe that 
probiotics have been tested for the management of constipation. This confirms the findings of a 
survey of GPs in the UK where only 6.3% reported that they had a good understanding of 
probiotics in general (19). This highlights a need to (i) improve the dissemination of the findings 
of published trials of specific probiotic strains in constipation, (ii) educate healthcare 
professionals on current evidence regarding the effectiveness of specific probiotic strains in 
constipation, and (iii) conduct further high quality RCTs in this area to identify novel probiotic 
strains that have the potential to improve constipation.  
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The probiotics most commonly used by the general public, and recommenced by GPs and GI 
specialists were not the same species/strains and were often not those with the greatest levels 
of evidence. The probiotics most commonly used by people with constipation were the 
probiotic-containing food products Activia (B. lactis DN-173010), Actimel (L. casei DN 114 001) 
and Yakult (L. casei Shirota). This is in agreement with the probiotic brands that patients with 
IBD also choose to use (20). Yakult was the probiotic most commonly recommended by GI 
specialists, while the probiotic supplement VSL#3 (a mixture of Streptococcus, Bifidobacterium 
and Lactobacillus strains) was the most commonly recommended by GPs. Indeed, various 
probiotic strains have been shown to have beneficial effects on several constipation-related 
symptoms, such as Bifidobacteria lactis (6; 7; 8). However, a systematic-review and meta-analysis 
showed, based on studies published to date, that L. casei Shirota (Yakult) did not improve 
symptoms in people with chronic constipation (8), while no study has been previously published 
on the effect of L. casei DN 114 001 (Actimel) on constipation. Therefore, it appears that the 
choice of the probiotic brands used by the general population and doctors is not necessarily 
driven by the current scientific evidence available, but could instead be driven by other factors, 
such as product availability or advertisement. 
This is also the first study to investigate the predictors of probiotic use in constipation. 
Interestingly, one of the strongest predictors for probiotic use for health in the general 
population was having constipation (self-reported or a formal medical diagnosis). Another 
interesting striking finding was that a strong predictor for probiotic use in those without self-
reported constipation was also the fulfilment of the Rome IV criteria for chronic constipation. 
Therefore, even though certain people did not believe they had constipation, those that met 
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the formal diagnostic criteria for chronic constipation were more likely to use probiotics for 
health than those who did not meet these criteria. A possible reason for this could be that 
these people do experience constipation-related symptoms included in the formal criteria, but 
that these symptoms are not burdensome to the individual or severe enough to lead to a 
perception that they have constipation. Nevertheless, these symptoms appear important 
enough to lead people to consume probiotics for their own digestive comfort. This is of major 
importance as it shows that the presence of certain symptoms, even though they are not 
perceived to be important or severe enough to result in self-reporting of constipation, may still 
lead people to seek relief from probiotics. A possible reason why probiotics are the therapy 
they choose is because they believe there is evidence they effectively manage constipation; 
indeed, our analysis showed that believing probiotics have been tested in research for their 
effectiveness in constipation was a significant predictor for probiotic use for the management 
of gut health among the general population. Furthermore, the strongest predictor for probiotic 
use by people without current self-reported constipation was having received a formal 
diagnosis of constipation in the past by a medical practitioner. It is hence feasible that such 
patients are now successfully managing their symptoms and do not consider themselves 
constipated any longer. 
As expected, older age and female gender were significant predictors of probiotic use for gut 
health by people with or without self-reported constipation. It is possible that older people 
have been experiencing constipation or gut symptoms for longer and thus have investigated 
and tried a wide range of different products, including probiotics, to manage their symptoms. 
Females were also shown to be more likely to use probiotics than males. These findings could 
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be explained by the fact that constipated women report significantly worse QoL compared to 
constipated men (21). Therefore, women may be more likely to seek some sort of treatment for 
their symptoms than men. Indeed, a previous study has confirmed that constipated subjects 
seeking medical care are most likely to be women (22). Furthermore, having a university degree 
significantly predicted the use of probiotics in the general population, emphasising the impact 
of education on health choices. 
Strengths of this study include the use of a control group drawn from the same population (i.e. 
general population without constipation). The sample size of this study was large and the 
recruitment was not region-specific, as most of the advertisements and newsletters were 
nationwide, in an effort to obtain a more representative sample of the UK population. Indeed, 
the findings show that the ethnicity of the study population is representative of that of the UK 
population (16). Furthermore, several evidence-based techniques were used in this study, such 
as using a non-monetary incentive, to maximise response rates (13). A limitation of the study is 
the fact that this questionnaire was only available to the general population via the internet, as 
well as that it was advertised in universities, websites, online magazines, online newspapers, 
and online volunteer databases, all of which could introduce selection bias. In the absence of a 
previously validated questionnaire on this topic, the questionnaire was developed de novo , and 
although it was piloted for comprehensibility it did not undergo psychometric testing for 
validity and reliability. Furthermore, the members of the general population were able to self-
report constipation that could have been either primary or secondary to medication or 
diseases, and no distinction between primary vs secondary constipation was made for the data 
analysis. Moreover, the use of a quantitative cross-sectional design did not allow capture of the 
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complete perceptions of the study participants, and could not provide data on the reasons 
behind participants’ behaviour and attitudes towards probiotic use. 
To conclude, this is the first study to demonstrate that significantly more people with 
constipation use probiotics compared to those without constipation suggesting they do believe 
probiotics to be effective in the management of their constipation-related symptoms. A strong 
predictor for probiotic use for constipation in the general population is having constipation 
(self-reported or formally diagnosed by a medical practitioner). The influence of TV adverts in 
choosing a treatment for constipation was also emphasised as this was shown to be the most 
common source of information for probiotics in the general population. Finally, education of 
health care professionals is needed on the prevalence of use of probiotics by the general 
population and by those with constipation, together with the current evidence for the 
effectiveness of specific strains of probiotics in constipation. 
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